北美细胞和基因治疗制造服务市场预测至 2030 年 - 区域分析 - 按类型 [细胞治疗（自体和同种异体）和基因治疗（病毒和非病毒载体）]、适应症（癌症、骨科等）、应用（临床制造和商业制造）和最终用户 [制药和生物技术公司和合同研究组织 (CRO)]
No. of Pages: 110 | Report Code: BMIRE00029298 | Category: Life Sciences
No. of Pages: 110 | Report Code: BMIRE00029298 | Category: Life Sciences
细胞和基因治疗制造是一个复杂的过程，这使得正确执行和监督操作至关重要。细胞和基因治疗制造商了解生物和工艺工程的合格人员数量有限。此外，对于经验丰富的团队来说，使用手动和开放制造方法来管理首次临床试验的尝试，然后构建更适合商业的流程可能会很棘手。因此，这些企业选择与合同开发和制造组织（CDMO）合作来加速其临床研究和商业化进程。 CDMO 以合同形式向细胞和基因治疗公司提供产品开发、制造、临床试验支持和商业化服务。与 CDMO 合作可以帮助细胞和基因治疗制造商实现可扩展性、加快上市速度、无需管理成本即可获得技术专业知识以及成本效率。 2022年4月，ThermoGenesis在美国加利福尼亚州建立了CDMO设施，利用其在T细胞受体（TCR）、嵌合抗原受体-T细胞（CAR-T细胞）、肿瘤等领域的专业知识，为细胞和基因治疗制造商提供CDMO服务。 -浸润白细胞（TIL）、iPSC、自然杀伤细胞（NK）和间充质干细胞（MSC）制造。事实证明，将细胞和基因治疗制造外包给 CDMO 对于制造商来说具有成本效益。因此，越来越倾向于将不断增长的细胞和基因治疗制造外包给 CDMO，这推动了北美细胞和基因治疗制造服务市场的增长。
细胞和基因疗法（CGT）治疗患有严重和罕见疾病且治疗需求未得到满足的患者。制造 CGT 是一个高度复杂的过程，基础设施和专业知识的不足是一个主要限制因素。与中间体和最终产品相关的物流挑战也限制了公司的 CGT 制造能力。 CGT的制造过程包括通过“单采术”提取自体细胞，将其送往专门实验室，然后送回诊所给患者施用，所有这些都必须在严格的质量控制下进行。美国食品和药物管理局 (USFDA) 仅批准了 7 种 CGT 药物，新产品管线达到约 1,200 种实验疗法。其中一半处于 2 期临床试验中，根据 Chemical & Research 的估计，细胞疗法的年销售额增长预计为 15%，基因疗法的年销售额增长约为 30%。 Engineering News 报道 2022。2022 年 3 月 31 日，CELL Technologies Inc. 宣布提交其疼痛和关节炎干细胞项目的临床数据，以供加拿大卫生部批准，以帮助患者获得基于证据和监管批准的干细胞程序横跨加拿大。因此，预计上述因素将在预测期内促进细胞和基因治疗制造服务市场的增长。因此，上述因素是北美细胞和基因治疗制造服务市场增长的原因。
北美细胞和基因治疗制造服务市场细分分为类型、适应症、应用、最终用户和国家。
根据类型，北美细胞和基因治疗制造服务市场分为细胞治疗和基因治疗。 2022年，细胞治疗领域在北美细胞和基因治疗制造服务市场中占据更大份额。细胞治疗部分进一步分为自体细胞治疗和同种异体细胞治疗。基因治疗细分市场进一步细分为病毒和非病毒载体。
根据适应症，北美细胞和基因治疗制造服务市场细分为癌症、骨科等。 2022年，癌症细分市场在北美细胞和基因治疗制造服务市场中占据最大份额。
根据应用，北美细胞和基因治疗制造服务市场分为临床制造和商业制造制造业。 2022年，商业制造领域在北美细胞和基因治疗制造服务市场中占据最大份额。
根据最终用户，北美细胞和基因治疗制造服务市场分为制药和基因治疗服务市场。生物技术公司和合同研究组织 (CRO)。 2022年，制药和生物技术公司细分市场在北美细胞和基因治疗制造服务市场中占据更大份额。
根据国家/地区，北美细胞和基因治疗制造服务市场细分为美国、加拿大、墨西哥。 2022年，美国在北美细胞和基因治疗制造服务市场占据最大份额。
Catalent Inc、Charles River Laboratories International Inc、FUJIFILM Holdings Corp、Lonza Group AG、Merck KgaA、National Resilience Inc、Nikon Corp、Oxford BioMedica Plc、Takara Bio Inc、Thermo Fisher Scientific Inc 和 WuXi AppTec Co Ltd 是北美细胞和基因治疗制造服务市场上的一些领先公司。
Strategic insights for North America Cell and Gene Therapy Manufacturing Services involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 4,153.27 Million |
| Market Size by 2030 | US$ 14,711.72 Million |
| Global CAGR (2022 - 2030) | 17.1% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Cell and Gene Therapy Manufacturing Services refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
1. Catalent Inc
2. Charles River Laboratories International Inc
3. FUJIFILM Holdings Corp
4. Lonza Group AG
5. Merck KgaA
6. National Resilience Inc
7. Nikon Corp
8. Oxford BioMedica Plc
9. Takara Bio Inc
10. Thermo Fisher Scientific Inc
11. WuXi AppTec Co Ltd?
The North America Cell and Gene Therapy Manufacturing Services Market is valued at US$ 4,153.27 Million in 2022, it is projected to reach US$ 14,711.72 Million by 2030.
As per our report North America Cell and Gene Therapy Manufacturing Services Market, the market size is valued at US$ 4,153.27 Million in 2022, projecting it to reach US$ 14,711.72 Million by 2030. This translates to a CAGR of approximately 17.1% during the forecast period.
The North America Cell and Gene Therapy Manufacturing Services Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Cell and Gene Therapy Manufacturing Services Market report:
The North America Cell and Gene Therapy Manufacturing Services Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Cell and Gene Therapy Manufacturing Services Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Cell and Gene Therapy Manufacturing Services Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Cell and Gene Therapy Manufacturing Services Market
